我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

高血压并发症与患者血清可溶性CD40及CD40L水平的关系(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2006年第2期
页码:
231-233
栏目:
临床研究
出版日期:
2006-03-01

文章信息/Info

Title:
The association between hypertensive complications and serum levels of soluble CD40/CD40L in patients with cardiovascular diseases
作者:
袁铭1; 吴宗贵2; 黄佐2; 殷仁富2; 梁春2; 唐可3
1.第四军医大学西京医院心脏内科, 陕西 西安 710032； 2. 第二军医大学长征医院心脏内科；3. 解放军411医院心内科，上海 200003
Author(s):
YUAN Ming1;  WU Zong-gui2;  HUANG Zuo2;  YIN Ren-fu2;  LIANG Chun2; TANG Ke3
1.Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi′an, Shaanxi, 710032; 2. Department of Cardiology, Changzheng Hospital, Second Military Medical University
关键词:
高血压并发症;  CD40; CD40L
Keywords:
hypertensive complications;  CD40;  CD40L
分类号:
R331.3
DOI:
-
文献标识码:
A
摘要:
目的 探讨原发性高血压患者可溶性CD40/CD40L 水平变化。方法 根据WHO关于高血压器官损伤并发症的分类,将研究对象分为无并发症组、中度器官损伤及重度器官损伤组。应用酶联免疫反应法测定328名研究对象血清可溶性CD40 (sCD40) 及可溶性CD40L (sCD40L)水平。结果 ①与无并发症组（n=180)相比，sCD40 水平在重度器官损伤组（n=50）显著升高(39.9±2.6 vs 30.0±1.0） ng/ml,P<0.01；与中度器官损伤组（29.4±1.4） ng/ml, （n=98)比较，重度器官损伤组sCD40 水平也显著升高(P<0.01); ②与无并发症组相比，重度器官损伤组中血清 sCD40水平仅在中风组上调 ; ③sCD40L 在各组均无显著变化。 结论 血清sCD40/sCD40L 水平与高血压并发症的严重程度有关。
Abstract:
AIM To investigate the changes of soluble CD40/CD40L in patients with essential hypertension. METHODS In a hospitalbased and crosssectional study, we evaluated organ damages due to hypertension according to the World Health Organization (WHO) classification, including no complications, mild organ damages and severe organ damages. Serum soluble CD40 (sCD40) and soluble CD40L (sCD40L) levels were analyzed by commercially available ELISAs (Bender Med Systems, USA) in 328 patients. RESULTS Our main findings were: ①sCD40 was significantly increased in severe organ damage (39.9±2.6） ng/ml, （n=50) versus no complication (30.0±1.0） ng/ml, （n=180), P<0.01 and mild organ damage (29.4±1.4） ng/ml, （n=98）, P<0.01, respectively; however, no significant changes in the sCD40 were measured in mild organ damages; ②when evaluated in severe organ damages group, serum sCD40 tended to be upregulated in patients with stroke compared with controls (33.5±2.6） ng/ml, （n=97）, P<0.05; ③sCD40L didn't exhibit significant results in our study groups. CONCLUSION Our findings may suggest that the association between chronic inflammation and hypertension by observing the serum soluble CD40/CD40L levels and hypertensive complications can indicate some inflammatory state.

参考文献/References

［1］Laman JD, Claassen E, Noelle RJ. Functions of CD40 and its ligand, gp39 (CD40L) ［J］.Crit Rev Immunol ,1996,16:59-108.

［2］王崇良，贺美先，刘勇. 冠心病是炎症性疾病［J］. 心脏杂志，2003,15（2）:178-179.

［3］Aukrust P, Mller F, Ueland T, et al. Enhanced levels of soluble and membraneboundCD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes［J］. Circulation,1999, 100:614-620.

［4］Schnbeck U, Libby P.The CD40/CD154 receptor/ligand dyad［J］. Cell Mol Life Sci, 2001, 58:4-43.

［5］Garlichs CD, Kozina S, FatehMoghadam S, et al. Upregulation of CD40CD40 ligand (CD154) in patients with acute cerebral ischemia［J］. Stroke, 2003, 34:1412-1418.

［6］Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes［J］. Circulation, 2003, 108:1049-1052.

［7］Schnbeck U, Sukhova GK, Shimizu K, et al.Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice［J］. Proc Natl Acad Sci U S A ,2000, 97:7458-7463.

［8］Lutgens E, Cleutjens KBJM, Heeneman S, et al.Both early and delayed antiCD40L antibody treatment induces a stable plaque phenotype［J］. Proc Natl Acad Sci U S A, 2000, 97:7464-7469.

［9］Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones［J］. Circulation ,2003, 107:2664-2669.

［10］Semb AG, van Wissen S, Ueland T, et al.Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy［J］. J Am Coll Cardiol, 2003, 41:275-279.

［11］Jinchuan Y, Zonggui W, Jinming C,et al.Upregulation of CD40CD40 ligand system in patients with diabetes mellitus［J］. Clin Chim Acta ,2004, 339:85-90.

［12］Suo Z, Wu M, Ameenuddin S, et al.Participation of proteaseactivated receptor1 in thrombin-induced microglial activation［J］. J Neurochem, 2002, 80:655-666.

备注/Memo

备注/Memo:
收稿日期：2004-07-18.基金项目：上海市科学技术发展基金项目资助(No.102DJ140181) 作者简介：袁铭，主治医师，博士 Tel:(029)84775183 Email：yuanmingfmmu@tom.com
更新日期/Last Update: